| Health / Medical Topics |
MUC16-targeted Antibody-Drug Conjugate DMUC5754A
An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of DMUC5754A selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
Human MUC16 wild-type allele is located in the vicinity of 19q13.2 and is approximately 132 kb in length. This allele, which encodes…
This gene is involved in both cellular adhesion and the maintenance of mucosal surfaces.
An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit…
A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the…
A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH…
Human MUC1 wild-type allele is located within 1q21 and is approximately 121 kb in length. This allele, which encodes mucin-1 protein, plays…
